It has been reported that long-term use of continuous-flow mechanical circulatory support devices (CF-MCSDs) may induce complications associated with diminished pulsatility. Pulsatile-flow mechanical circulatory support devices (PF-MCSDs) have the potential of overcoming these shortcomings with the advance of technology. In order to promote in-depth understanding of PF-MCSD technology and thus encourage future mechanical circulatory support device innovations, engineering perspectives of PF-MCSD systems, including mechanical designs, drive mechanisms, working principles, and implantation strategies, are reviewed in this article. Some emerging designs of PF-MCSDs are introduced, and possible elements for next-generation PF-MCSDs are identified.
BenjaminEJBlahaMJChiuveSE, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation2017; 135: e146–e603.
2.
MurphyCZafarHSharifF.An updated review of cardiac devices in heart failure. Ir J Med Sci2017; 186(4): 909–919.
3.
KirklinJKNaftelDCKormosRL, et al. Second INTERMACS annual report: more than 1,000 primary left ventricular assist device implants. J Heart Lung Transplant2010; 29(1): 1–10.
4.
TimmsD.A review of clinical ventricular assist devices. Med Eng Phys2011; 33: 1041–1047.
5.
KirklinJKPaganiFDKormosRL, et al. Eighth annual INTERMACS report: special focus on framing the impact of adverse events. J Heart Lung Transplant2017; 36(10): 1080–1086.
6.
ChengAWilliamitisCASlaughterMS.Comparison of continuous-flow and pulsatile-flow left ventricular assist devices: is there an advantage to pulsatility. Ann Cardiothorac Surg2014; 3(6): 573–581.
7.
FrazierOH.Unforeseen consequences of therapy with continuous-flow pumps. Circ Heart Fail2010; 3(6): 647–649.
8.
SoucyKGKoenigSCGiridharanGA, et al. Defining pulsatility during continuous-flow ventricular assist device support. J Heart Lung Transplant2013; 32(6): 581–587.
9.
SoucyKGGiridharanGAChoiY, et al. Rotary pump speed modulation for generating pulsatile flow and phasic left ventricular volume unloading in a bovine model of chronic ischemic heart failure. J Heart Lung Transplant2015; 34(1): 122–131.
10.
DrewsTJurmannMMichaelD, et al. Differences in pulsatile and non-pulsatile mechanical circulatory support in long-term use. J Heart Lung Transplant2008; 27(10): 1096–1101.
11.
GiridharanGABartoliCRSpencePA, et al. Counterpulsation with symphony prevents retrograde carotid, aortic, and coronary flows observed with intra-aortic balloon pump support. Artif Organs2012; 36(7): 600–606.
12.
JohnRLeeSEckmanP, et al. Right ventricular failure—a continuing problem in patients with left ventricular assist device support. J Cardiovasc Transl Res2010; 3(6): 604–611.
13.
GiridharanGAEwertDLPantalosGM, et al. Left ventricular and myocardial perfusion responses to volume unloading and afterload reduction in a computer simulation. ASAIO J2004; 50(5): 512–518.
14.
TakedaJ.Experimental study on peripheral circulation during extracorporeal circulation. Kyoto, Japan: Kyoto University, 1960.
15.
BaricD.Why pulsatility still matters: a review of current knowledge. Croat Med J2014; 55(6): 609–620.
16.
VetterHOKaulbachHGSchmitzC, et al. Experience with the Novacor left ventricular assist system as a bridge to cardiac transplantation, including the new wearable system. J Thorac Cardiovasc Surg1995; 109(1): 74–80.
17.
MaherTRButlerKCPoirierVL, et al. HeartMate left ventricular assist devices: a multigeneration of implanted blood pumps. Artif Organs2001; 25(5): 422–426.
18.
FrazierOHMyersTJRadovancevićB.The HeartMate left ventricular assist system: overview and 12-year experience. Texas Heart Inst J1998; 25: 265–271.
19.
MehtaSMPaeWEJrRosenbergG, et al. The LionHeart LVD-2000: a completely implanted left ventricular assist device for chronic circulatory support. Ann Thorac Surg2001; 71(Suppl. 3): S156–S161, discussion S183.
20.
El-BanayosyAArusogluLKiznerL, et al. Preliminary experience with the LionHeart left ventricular assist device in patients with end-stage heart failure. Ann Thorac Surg2003; 75(5): 1469–1475.
SpanierTBChenJMOzMC, et al. Time-dependent cellular population of textured-surface left ventricular assist devices contributes to the development of a biphasic systemic procoagulant response. J Thorac Cardiovasc Surg1999; 118: 404–413.
23.
SlaughterMSMyersTJ.Transcutaneous energy transmission for mechanical circulatory support systems: history, current status, and future prospects. J Card Surg2010; 25(4): 484–489.
24.
YuYCAntakiJFBostonJR, et al. Mathematical model of pulsatile blood pump for LVAS control. ASAIO J1997; 6: 293–301.
25.
YuYCBostonJRSimaanMA, et al. Pressure-volume relationship of a pulsatile blood pump for ventricular assist device development. ASAIO J2001; 47(3): 293–301.
26.
McCarthyPMWangNVargoR.Preperitoneal insertion of the HeartMate 1000 IP implantable left ventricular assist device. Ann Thorac Surg1994; 57(3): 634–637, discussion 637.
27.
FrazierOHDuncanJMRadovancevicB, et al. Successful bridge to heart transplantation with a new left ventricular assist device. J Heart Lung Transplant1992; 11(3Pt. 1): 530–537.
28.
JansenPGMWheeldonDRPortnerPM, et al. Long term home discharge support with Novacor LVAS. J Heart Lung Transplant1999; 18: 67–68.
29.
LongJW.Advanced mechanical circulatory support with the HeartMate left ventricular assist device in the year 2000. Ann Thorac Surg2001; 71(Suppl. 3): S176–S182, discussion S183.
30.
PaeWEConnellJMAdelowoA, et al. Does total implantability reduce infection with the use of a left ventricular assist device? The LionHeart experience in Europe. J Heart Lung Transplant2007; 26(3): 219–229.
31.
WangJXSmithJRBondeP.Energy transmission and power sources for mechanical circulatory support devices to achieve total implantability. Ann Thorac Surg2014; 97(4): 1467–1474.
32.
SlaughterMS.Long-term continuous flow left ventricular assist device support and end-organ function: prospects for destination therapy. J Card Surg2010; 25(4): 490–494.
33.
GoheanJRGeorgeMJPateTD, et al. Verification of a computational cardiovascular system model comparing the hemodynamics of a continuous flow to a synchronous valveless pulsatile flow left ventricular assist device. ASAIO J2013; 59(2): 107–116.
34.
LetsouGVPateTDGoheanJR, et al. Improved left ventricular unloading and circulatory support with synchronized pulsatile left ventricular assistance compared with continuous-flow left ventricular assistance in an acute porcine left ventricular failure model. J Thorac Cardiovasc Surg2010; 140(5): 1181–1188.
35.
GoheanJRLarsonERHsiBH, et al. Scaling the low-shear pulsatile TORVAD for pediatric heart failure. ASAIO J2017; 63(2): 198–206.
PapaioannouTGMathioulakisDSStamatelopoulosKS, et al. New aspects on the role of blood pressure and arterial stiffness in mechanical assistance by intra-aortic balloon pump: in-vitro data and their application in clinical practice. Artif Organs2004; 28(8): 717–727.
38.
FerrariGKhirAWFresielloL, et al. Hybrid model analysis of intra-aortic balloon pump performance as a function of ventricular and circulatory parameters. Artif Organs2011; 35(9): 902–911.
39.
MeynsBPNishimuraYJashariR, et al. Ascending versus descending aortic balloon pumping: organ and myocardial perfusion during ischemia. Ann Thorac Surg2000; 70(4): 1264–1269.
40.
KapeliosCJTerrovitisJVSiskasP, et al. Counterpulsation: a concept with a remarkable past, an established present and a challenging future. Int J Cardiol2014; 172(2): 318–325.
41.
KrishnaMKaiZ.Principles of intra-aortic balloon pump counterpulsation. Contin Educ Anaesth Crit Care Pain2009; 9: 24–28.
42.
SlaughterMSSobieskiMGiridharanG, et al. Counter-pulsation devices for myocardial support. Cardiothor Surg Rev2011; 58: 353–362.
43.
KolyvaCPepperJRKhirAW.Newly shaped intra-aortic balloons improve the performance of counterpulsation at the semirecumbent position: an in vitro study. Artif Organs2016; 40(8): E146–E157.
44.
ThieleHZeymerUNeumannFJ, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med2012; 367: 1287–1296.
45.
ThieleHZeymerUNeumannF-J, et al. Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. Lancet2013; 382(9905): 1638–1645.
46.
GhiaSDhawanRChaneyMA, et al. Can I go home with that balloon pump. J Cardiothorac Vasc Anesth2018; 32(3): 1468–1479.
47.
JeevanandamVSongTOnsagerD, et al. The first-in-human experience with a minimally invasive, ambulatory, counterpulsation heart assist system for advanced congestive heart failure. J Heart Lung Transplant2018; 37(1): 1–6.
48.
SolankiP.Aortic counterpulsation: C-pulse and other devices for cardiac support. J Cardiovasc Transl Res2014; 7(3): 292–300.
49.
QureshiMB.Cardiac output improvement in mechanical circulatory support devices. Fargo, ND: North Dakota State University, 2017.
50.
JeevanandamVJayakarDAndersonAS, et al. Circulatory assistance with a permanent implantable IABP: initial human experience. Circulation2002; 106(12Suppl. 1): I183–I188.
51.
BlackMCSchumerEMRogersM, et al. Sunshine heart C-pulse: device for NYHA Class III and ambulatory Class IV heart failure. Future Cardiol2016; 12(5): 521–531.
52.
AbrahamWTAggarwalSPrabhuSD, et al. Ambulatory extra-aortic counterpulsation in patients with moderate to severe chronic heart failure. JACC Heart Fail2014; 2(5): 526–533.
53.
CecereRDowlingRDGiannettiN.Initial clinical experience with the symphony heart assist system. Ann Thorac Surg2015; 99(1): 298–301.
54.
WarrenSGiridharanGADowlingRD, et al. Feasibility of subcutaneous ECG leads for synchronized timing of a counterpulsation device. Cardiovasc Eng Tech2011; 3: 17–25.
55.
MalcheskyPS.Artificial organs 2012: a year in review. Artif Organs2013; 37: 324–349.
56.
DowlingRDEtochSWStevensKA, et al. Current status of the AbioCor implantable replacement heart. Ann Thorac Surg2001; 71(Suppl. 3): S147–S149, discussion S183.
57.
DowlingRDGrayLAJrEtochSW, et al. Initial experience with the AbioCor implantable replacement heart system. J Thorac Cardiovasc Surg2004; 127(1): 131–141.
DowlingRDGrayLAJEtochSW, et al. The AbioCor implantable replacement heart. Ann Thaorac Surg2003; 75: 7.
60.
KungRTOchsBSinghPI.A unique left-right flow imbalance compensation scheme for an implantable total artificial heart. ASAIO Trans1989; 35(3): 468–470.
61.
GerosaGScuriSIopL, et al. Present and future perspectives on total artificial hearts. Ann Cardiothorac Surg2014; 3(6): 595–602.
62.
SaleSMSmediraNG.Total artificial heart. Best Pract Res Clin Anaesthesiol2012; 26: 147–165.
63.
AhnJMKangDWKimHC, et al. In vivo performance evaluation of a transcutaneous energy and information transmission system for the total artificial heart. ASAIO J1993; 39(3): M208–M212.
64.
DowlingRDGrayLAJrEtochSW, et al. Initial experience with the AbioCor implantable replacement heart system. J Thorac Cardiovasc Surg2004; 127: 131–141.
65.
SlepianMJSmithRGCopelJG.The SynCardia CardioWest™ total artificial heart. In: BaughmanKLBaumgartnerWA (eds) Treatment of advanced heart disease. London: Taylor & Francis; 2006, pp. 473–490.
66.
SpiliopoulosSKoerferRTenderichG.A first step beyond traditional boundaries: destination therapy with the SynCardia total artificial heart. Interact Cardiovasc Thorac Surg2014; 18(6): 855–856.
67.
SlepianMJAlemuYGirdharG, et al. The Syncardia total artificial heart: in vivo, in vitro, and computational modeling studies. J Biomech2013; 46(2): 266–275.
68.
GrayNAJrSelzmanCH.Current status of the total artificial heart. Am Heart J2006; 152: 4–10.
69.
BarnardJTsuiSS.The total artificial heart in a cardiac replacement therapy programme. Br J Hosp Med2012; 73(12): 672–676.
70.
JaroszewskiDEAndersonEMPierceCN, et al. The SynCardia freedom driver: a portable driver for discharge home with the total artificial heart. J Heart Lung Transplant2011; 30(7): 844–845.
CopelandJGSmithRGArabiaFA, et al. Cardiac replacement with a total artificial heart as a bridge to transplantation. N Engl J Med2004; 351(9): 859–867.
73.
TorregrossaGMorshuisMVargheseR, et al. Results with SynCardia total artificial heart beyond 1 year. ASAIO J2014; 60(6): 626–634.
74.
LatremouilleCDuveauDCholleyB, et al. Animal studies with the Carmat bioprosthetic total artificial heart. Eur J Cardiothorac Surg2015; 47(5): e172–e178, discussion e178.
75.
JansenPvan OeverenWCapelA, et al. In vitro haemocompatibility of a novel bioprosthetic total artificial heart. Eur J Cardiothorac Surg2012; 41(6): e166–e172.
76.
KoerferRSpiliopoulosSFinocchiaroT, et al. Paving the way for destination therapy of end-stage biventricular heart failure: the ReinHeart total artificial heart concept. Eur J Cardiothorac Surg2014; 46(6): 935–936.
77.
PelletierBSpiliopoulosSFinocchiaroT, et al. System overview of the fully implantable destination therapy–ReinHeart-total artificial heart. Eur J Cardiothorac Surg2015; 47(1): 80–86.
78.
GrafFRossbroichRFinocchiaroT, et al. Investigation of the durability of a diaphragm for a total artificial heart. Artif Organs2016; 40(10): 1016–1022.
79.
Cuenca-NavalonELaumenMFinocchiaroT, et al. Estimation of filling and afterload conditions by pump intrinsic parameters in a pulsatile total artificial heart. Artif Organs2016; 40(7): 638–644.
80.
MaromGChiuWCSlepianMJ, et al. Numerical model of total artificial heart hemodynamics and the effect of its size on stress accumulation. Conf Proc IEEE Eng Med Biol Soc2014; 2014: 5651–5654.
81.
SchumerEMBlackMCMonrealG, et al. Left ventricular assist devices: current controversies and future directions. Eur Heart J2016; 37(46): 3434–3439.
82.
PetukhovDSSelishchevSVTelyshevDV.Prospects for development of technologies for complete replacement of heart function by mechanical circulatory support systems. Biomed Eng2016; 49: 258–262.
83.
EssandohMEssandohGStallkampEDJr, et al. Spectral Doppler analysis of the HeartMate 3 left ventricular assist device inflow: new challenges presented by the artificial pulse technology. J Cardiothorac Vasc Anesth2018; 32(6): e4–e5.
84.
WiegmannLThamsenBde ZelicourtD, et al. Fluid dynamics in the HeartMate 3: influence of the artificial pulse feature and residual cardiac pulsation. Artif Organs2019; 43(4): 363–376.
85.
KumarJElhassanADimitrovaG, et al. The Lavare Cycle: a novel pulsatile feature of the HVAD continuous-flow left ventricular assist device. J Cardiothorac Vasc Anesth2019; 33(4): 1170–1171.
86.
RintoulTCDolginA.Thoratec transcutaneous energy transformer system: a review and update. ASAIO J2004; 50(4): 397–400.
87.
WatersBHSampleAPBondeP, et al. Powering a Ventricular Assist Device (VAD) with the Free-Range Resonant Electrical Energy Delivery (FREE-D) system. Proc IEEE2012; 100: 138–149.
88.
WatersBHSmithJRBondeP.Innovative Free-range Resonant Electrical Energy Delivery system (FREE-D system) for a ventricular assist device using wireless power. ASAIO J2014; 60(1): 31–37.
89.
AsgariSSBondeP.Implantable physiologic controller for left ventricular assist devices with telemetry capability. J Thorac Cardiovasc Surg2014; 147(1): 192–202.
90.
BonowROCarabelloBAChatterjeeK, et al. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. J Am Coll Cardiol2008; 52: e1–e142.
91.
BluesteinD.Research approaches for studying flow-induced thromboembolic complications in blood recirculating devices. Expert Rev Med Devices2004; 1(1): 65–80.
92.
FiorettaESDijkmanPEEmmertMY, et al. The future of heart valve replacement: recent developments and translational challenges for heart valve tissue engineering. J Tissue Eng Regen Med2018; 12(1): e323–e335.
